Impairment of membrane markers on peripheral blood mononuclear cells and imbalance of cytokine secretion in the pathogenesis of multiple sclerosis active phases

Journal of Interferon and Cytokine Research

Volumn 25, Issue 11, 2005, Pages 661-665

  Sofo, Vincenza ^a   Salmeri, Francesca Maria ^a   Di Bella, Paolo ^a   Sessa, Edoardo ^a   D'Aleo, Giangaetano ^a   Trimarchi, Giuseppe ^b   Bramanti, Placido ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; CELL MEMBRANE MARKER; CYTOKINE; FAS ANTIGEN; FAS LIGAND; MYELIN; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; FASLG PROTEIN, HUMAN; MEMBRANE PROTEIN; TUMOR NECROSIS FACTOR;

ADULT; APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE MIGRATION; MALE; MULTIPLE SCLEROSIS; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL; TH2 CELL; BIOSYNTHESIS; BLOOD; CELL MEMBRANE; CELL MOTION; CHEMISTRY; INFLAMMATION; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; MYELIN SHEATH; NUCLEAR MAGNETIC RESONANCE IMAGING;

ADULT; ANTIGENS, CD40; ANTIGENS, CD95; APOPTOSIS; CELL MEMBRANE; CELL MOVEMENT; CYTOKINES; FAS LIGAND PROTEIN; FEMALE; HUMANS; INFLAMMATION; LEUKOCYTES, MONONUCLEAR; MAGNETIC RESONANCE IMAGING; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELIN SHEATH; T-LYMPHOCYTES; TH1 CELLS; TH2 CELLS; TUMOR NECROSIS FACTORS;

EID: 29444456900     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2005.25.661     Document Type: Article

References (55)

1. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 1992;10:153-187.
2. Weinshenker BG. Natural history of multiple sclerosis. Ann. Neurol. 1994;36(Suppl.):S6-S11.
3. Sorensen TL, Ransohoff RM. Etiology and pathogenesis of multiple sclerosis. Semin. Neurol. 1998;18:287-294.
4. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N. Engl. J. Med. 2000;343:938-952.
5. Hohlfeld R, Wekerle H. Immunological update on multiple sclerosis. Curr. Opin. Neurol. 2001;14:299-304.
6. Riekmann P, Smith KJ. Multiple sclerosis: more than inflammation and demyelination. Trends Neurosci. 2001;24:435-437.
7. Cannella B, Cross AH, Raine CS. Upregulation and coexpression of adhesion molecules correlate with relapsing autoimmune demyelination in the central nervous system. J. Exp. Med. 1990;172: 1521-1524.
8. Eikelenboom MJ, Killestein J, Izeboud T, Kalkers NF, Baars PA, van Lier RAW, Barkhof F, Uitdehaag BJ, Polman CH. Expression of adhesion molecules on peripheral lymphocytes predicts future lesion development in MS. J. Neuroimmunol. 2005;158: 222-230.
9. Chou Y, Bourdette D, Offner H, Witham R, Wang R, Hasheim G. Frequency of T cells specific for myelin basic protein and myelin proteolipid protein in blood and cerebrospinal fluid in multiple sclerosis. J. Neuroimmunol. 1992;38:105-114.
10. Raine CS. The D.E. McFarlin Memorial Lecture: the immunology of multiple sclerosis. Ann. Neurol. 1994;36:S61-S72.
11. Wingerchuk DM, Lucchinetti CF, Noseworthy JH. Multiple sclerosis: current pathophysiological concepts. Lab. Invest. 2001;81:263-281.
12. Steinman L. Multiple sclerosis: a two stage disease. Nat. Immunol. 2001;2:762-764.
13. Huitinga I, Ruuls SR, Jung S, Van Rooijen N, Hartung HP, Dijkstra CD. Macrophages in T cell line-mediated, demyelinating, and chronic relapsing experimental autoimmune encephalomyelitis in Lewis rats. Clin. Exp. Immunol. 1995;100:344-351.
14. Zipp F. Apoptosis in multiple sclerosis. Cell Tissue Res. 2000;301:163-171.
15. Beck J, Rondot P, Catinot L, Falcoff E, Kirchner A, Wilizerbin J. Increased production of IFN-γ and TNF precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbation? Acta Neurol. Scand. 1988;78:1985-1996.
16. Zoukos Y, Kidd D, Woodroofe MN, Kendal BE, Thompson AJ, Cuzner ML. Increased expression of high affinity IL-2 receptors and beta-adrenoceptors on peripheral blood cells is associated with clinical and MRI activity in multiple sclerosis. Brain 1994;117:307-315.
17. Alderson MR, Tough TW, Davis-Smith T, Braddy S, Falk B, Schooley KA, Goodwin RG, Smith CA, Ramsdell F, Lynch DH. Fas ligand mediated activation induced cell death in human T lymphocytes. J. Exp. Med. 1995;181:71-77.
18. + T cells via CD40 ligand. Proc. Natl. Acad. Sci. USA 1997;94:599-603.
19. Locksley RM, Killeen N, Lenardo MI. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001;104:487-500.
20. Lenardo M, Chan KM, Hormung F, McFarland H, Siegel R, Wang J, Zheng L. Mature T lymphocyte apoptosis-immune regulation in a dynamic and unpredictable antigenic environment. Annu. Rev. Immunol. 1999;17:221-253.
21. Krammer PH. CD95's deadly mission in the immune system. Nature 2000;407:789-795.
22. Siegel RM, Chan FK, Chun HI, Lenardo MI. The multifacted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat. Immunol. 2000;1:469-474.
23. Osborne BA. Apoptosis and the maintenance of homeostasis in the immune system. Curr. Opin. Immunol. 1996;8:245-254.
24. Lenardo MI. The molecular regulation of lymphocyte apoptosis. Semin. Immunol. 1997;9:1-5.
25. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tortellotte WW. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 1983;13:227-231.
26. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33: 1444-1452.
27. Reinherz EL, Kung PC, Goldstein G, Schlossman SF. Separation of functional subsets of human T cells by monoclonal antibody. Proc. Natl. Acad. Sci. USA 1979;76:4061-4072.
28. Siegel S, Castellan NJ. Nonparametric Statistics for Behavioural Science. London, U.K.: McGraw-Hill Education, 1988.
29. Karmann K, Hughes, C, Schechner J, Fanslow WC, Pober JS. CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc. Natl. Acad. Sci. USA 1995;92:4342-4346.
30. Grewal IS, Foellmer HG, Grewal KD, Xu J, Hardardottir F, Baron JL, Janeway CA Jr, Flavell RA. Requirement for CD40 ligand in costimulation induction, T cell activation and experimental allergic encephalomyelitis. Science 1996;273:1864-1867.
31. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 1998;16:111-135.
32. van Kooten C, Banchereau J. CD40-CD40 ligand. J. Leukoc. Biol. 2000;67:2-17.
33. Schonbeck U, Libby P. CD40 signaling and plaque instability. Circ. Res. 2001;89:1092-1103.
34. Fanslow WC, Srinivasan S, Paxton R, Gibson MG, Spriggs MK, Armitage RJ. Structural characteristics of CD40 ligand that determine biological function. Semin. Immunol. 1994;6:267-278.
35. Link H. The cytokine storm in multiple sclerosis. Mult. Scler. 1998;4:12-15.
36. Huang WX, Huang P, Link H, Hillert J. Cytokine analysis in multiple sclerosis by competitive RT-PCR: a decreased expression of IL-10 and an increased expression of TNF-alpha in chronic progression. Mult. Scler. 1999;5:342-348.
37. Teleshova N, Bao W, Kivisäkk P, Özenci V, Mustafa M, Link H. Elevated CD40 ligand expressing blood T-cell levels in multiple sclerosis are reversed by interferon-beta treatment. Scand. J. Immunol. 2000;51:312-320.
38. Huang WX, Huang P, Hillert J. Systemic upregulation of CD40 and CD40 ligand mRNA expression in multiple sclerosis. Mult. Scler. 2000;6:61-65.
39. Jacob CO, Lewis GD, McDevitt HO. MHC class II-associated variation in the production of tumor necrosis factor in mice and in humans: relevance to the pathogenesis of autoimmune diseases. Immunol. Rev. 1991;10:156-168.
40. Baxter TG, Kuo RC, Orla JJ, Vandenabeele P, MacEwan DJ. Tumor necrosis factor-α mediates both apoptotic cell death and cell proliferation in a human hematopoietic cell line dependent on mitotic activity and receptor subtype expression. J. Biol. Chem. 1999;274:9539-9547.
41. Wallach D, Varfolomeev EE, Malinin NL, Kovalenko YV, Boldin MP. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu. Rev. Immunol. 1999;17:331-367.
42. Roulston A, Reinhard C, Amiri P, Williams LT. Early activation of c-Jun N-terminal kinase and p-38 kinase regulate cell survival in response to tumor necrosis factor-α. J. Biol. Chem. 1998;273: 10232-10238.
43. Nagata S, Goldstein P. The Fas death factor. Science 1995;267:1449-1456.
44. Miyawaki T, Uehara T, Nibu R, Tsuij T, Yachie A, Yonehara S, Taniguchi N. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J. Immunol. 1992;149:3753-3758.
45. Drein J, Walczak H, Baumler C, Dabatin KM, Krammer PH. Autocrine T cell suicide mediated by Apo-1 (Fas/CD95). Nature 1995;373:438-444.
46. Bonetti B, Raine CS. Multiple sclerosis oligodendrocytes display cell death-related molecules in situ but do not undergo apoptosis. Ann. Neurol. 1997;42:74-84.
47. Macchi B, Matteucci C, Nocentini U, Caltagirone C, Mastino A. Impaired apoptosis in mitogen-stimulated lymphocytes of patients with multiple sclerosis. Neuroreport 1999;10:399-402.
48. Segal BM, Cross AH. Fas(t) track to apoptosis in MS: TNF receptors may suppress or potentiate CNS demyelinating. Neurology 2000;55:906-907.
49. Ichikawa H, Ota K, Iwata M. Increased Fas antigen on T cells in multiple sclerosis. J. Neuroimmunol. 1996;71:125-129.
50. Ferrante P, Fusi ML, Saresella M, Caputo D, Biasin M, Trabattoni D, Salvaggio A, Clerici E, de Vries JE, Aversa G, Cazzullo CL, Clerici M. Cytokine production and surface marker expression in acute and stable multiple sclerosis: altered IL-12 production and augmented signaling lymphocytic activation molecule (SLAM)-expressing lymphocytes in acute multiple sclerosis. J. Immunol. 1998;160:1514-1521.
51. Huang WX, Huang, MP, Gomes MA, Hillert J. Apoptosis mediators FasL and TRAIL are upregulated in peripheral blood mononuclear cells in MS. Neurology 2000;55:928-934.
52. Gomes AC, Jonsson G, Mjornheim S, Olsson T, Hillert J, Grandien A. Upregulation of the apoptosis regulators cFLIP, CD95 and CD95 ligand in peripheral blood mononuclear cells in relapsing-remitting multiple sclerosis. J. Neuroimmunol. 2003;135:126-134.
53. Lopatinskaya L, van Boxel-Dezaire AH, Barkhof F, Polman CH, Lucas CJ, Nagelkerken L. The development of clinical activity in relapsing-remitting MS is associated with a decrease of FasL mRNA and an increase of Fas mRNA in peripheral blood. J. Neuroimmunol. 2003;138:123-131.
54. Petelin Z, Brinar V, Petravic D, Zurak N, Dubravcic K, Batinic D. CD95/Fas expression on peripheral blood T lymphocytes in patients with multiple sclerosis: effect of high-dose methylprednisolone therapy. Clin. Neurol. Neurosurg. 2004;106:259-262.
55. Bachmann R, Eugster HP, Frei K, Fontana A, Lassmann H. Impairment of TNF-receptor-I signaling but not Fas signaling diminished T cell apoptosis in myelin oligodendrocyte glycoprotein peptide-induced chronic demyelinating autoimmune encephalomyelitis in mice. Am. J. Pathol. 1999;154:1417-1422.